source
- Altimmune's pemvidutide cuts heavy drinking days in Phase 2 trialAltimmune reported that its experimental GLP-1/GIP injection pemvidutide achieved its primary and key secondary goals in a Phase 2 study of alcohol use disorder. The double-blind trial enrolled 10…
- FDA’s AI push faces uncertainty after key leaders departThe FDA has been pushing artificial intelligence across the agency, unveiling a large-language-model tool called Elsa to help draft and summarize review reports and announcing plans to use agentic…